Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-NEXT: Upifitamab rilsodotin as post-platinum maintenance therapy in recurrent platinum-sensitive ovarian cancer
2021-005099-21Phase 3Completed
- Sponsor
- Mersana Therapeutics
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing Upifitamab rilsodotin maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Jul 2022; status: completed.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2021-005099-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005099-21.